Body Habitus Changes and Metabolic Alterations in Protease Inhibitor–Naive HIV-1–Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors

Abstract

Treatment with NRTIs may be responsible for the same morphologic alterations as those observed in patients treated with PIs. Moreover, altered triglyceride levels are also frequently observed. The different timing of presentation and gender distribution of BHCs suggest that multiple pathogenetic mechanisms are involved.

References

Page 1

	Year	Citations
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors Andrew Carr, Katherine Samaras, Samantha Burton, AIDS	1998	2.4K
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study Andrew Carr, Katherine Samaras, Gilbert R. Kaufmann, The Lancet ObesityMetabolic SyndromeCardiovascular DiseaseHiv-1 Protease-inhibitor-associated LipodystrophyAcohort Study	1999	1.5K
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Carl Grünfeld, M Pang, William T. Doerrler, The Journal of Clinical Endocrinology & Metabolism Primary ImmunodeficiencyInflammationMetabolic SyndromeLipid DisorderMedicine	1992	811
Visceral abdominal-fat accumulation associated with use of indinavir Kirk D. Miller, Elizabeth C. Jones, Jack A. Yanovski, The Lancet ObesityMetabolic SyndromeVisceral Abdominal-fat AccumulationBody CompositionGastroenterology	1998	714
A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome Andrew Carr, J. Philip Miller, Matthew Law, AIDS	2000	640
A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy T Saint-Marc, M Partisani, Isabelle Poizot-Martin, AIDS	1999	594
“Buffalo hump” in men with HIV-1 infection Joan C. Lo, Kathleen Mulligan, Viva Tai, The Lancet Primary ImmunodeficiencySexual HealthHuman RetrovirusVirologyHiv-1 Infection	1998	574
Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients Ravi Walli, Oliver Herfort, Gerlinde M. Michl, AIDS	1998	536
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors Georg M. N. Behrens, André Dejam, Hartmut Schmidt, AIDS	1999	525
Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection Kathleen Mulligan, Carl Grünfeld, Viva Tai, JAIDS Journal of Acquired Immune Deficiency Syndromes ObesityMetabolic SyndromeBody CompositionProtease InhibitorProtease Inhibitors Independent	2000	499

Page 1